Markwell Clarizio LLP

Menu
Contact Us

Author name: David Park

Federal Court of Appeal Interprets “Use” in Section 42 of the Patent Act

IP Decisions /

The Federal Court of Appeal (per Heckman J.A.) dismissed an appeal by Steelhead LNG (ASLNG) Ltd. and Steelhead LNG Limited Partnership (collectively, “Steelhead”) from a summary trial judgment dismissing Steelhead’s patent infringement action. This appeal turned on the meaning of “use” under section 42 of the Patent Act. Steelhead LNG (ASLNG) Ltd v Arc Resources […]

Federal Court of Appeal Interprets “Use” in Section 42 of the Patent Act Read More »

Federal Court Finds Flaws in Online Survey Evidence and Reminds About Descriptive Certification Marks

IP Decisions /

The Federal Court (Tsimberis J.) dismissed an appeal by Promotion in Motion, Inc. (“PIM”) from a Trademark Opposition Board (“Board”) decision refusing PIM’s applications to register its SWISSKISS mark and SWISSKISS & Design mark in association with “chocolate of Swiss origin”. Hershey Chocolate & Confectionary LLC (“Hershey”) successfully opposed PIM’s applications based on Hershey’s registered

Federal Court Finds Flaws in Online Survey Evidence and Reminds About Descriptive Certification Marks Read More »

Federal Court Determines Admissibility of Testimony from Fact Witnesses who Authored Prior Art

IP Decisions /

In Medexus Pharmaceuticals v Accord Healthcare (2024 FC 424), Justice Pallotta dismissed the plaintiffs’ (“Medexus”) patent infringement action after finding that the patent at issue (“662 Patent”) was invalid for obviousness. The 662 Patent related to concentrations of subcutaneously injected methotrexate solutions used to treat rheumatoid arthritis and psoriasis/psoriatic arthritis. The decision addresses an interesting

Federal Court Determines Admissibility of Testimony from Fact Witnesses who Authored Prior Art Read More »

Generic Manufacturers Induce Patent Infringement by Recommending Use of a Patented Dosing Regimen in their Product Monographs

IP Decisions /

In Apotex v Janssen (2024 FCA 9) and Pharmascience v Janssen (2024 FCA 10), the Federal Court of Appeal held that Apotex and Pharmascience would induce patent infringement by recommending that their respective generic products be sold and used according to the dosing regimen claimed in Janssen’s 335 Patent. Apotex Inc. v. Janssen Inc. –

Generic Manufacturers Induce Patent Infringement by Recommending Use of a Patented Dosing Regimen in their Product Monographs Read More »

Federal Court Determines the Inventive Concept of an Improved Drug Formulation

IP Decisions /

In this Federal Court decision (per Pentney J.), the plaintiffs Allergan and AbbVie (“Allergan”) were successful in upholding the validity of their 691 Patent. The defendant (“Juno”) conceded that its proposed generic drug product would infringe the 691 Patent. The main issues before the Court were obviousness and sufficiency. Allergan v Juno, 2023 FC 1686

Federal Court Determines the Inventive Concept of an Improved Drug Formulation Read More »

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part III

IP Decisions /

Co-written with Dino Clarizio This is the third of a series of three posts discussing some of the issues addressed by the trial judge (McVeigh J.) in NCS v Kobold, 2023 FC 1486. The three issues we discuss are those that arise less frequently in patent cases. They are: Topic 1: Priority Date (Post #1)Topic

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part III Read More »

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part II

IP Decisions /

Co-written with Dino Clarizio This is the second of a series of three posts discussing some of the issues addressed by the trial judge (McVeigh J.) in NCS v Kobold, 2023 FC 1486. The three issues we discuss are those that arise less frequently in patent cases. They are: Topic 1: Priority Dates (Post #1)Topic

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part II Read More »

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part I

IP Decisions /

Co-written with Dino Clarizio In a complex patent infringement action involving five NCS patents and one Kobold patent relating to tools and sleeves used in oil well drilling, the Federal Court (per McVeigh J.) held that NCS’s patents were invalid and not infringed, and that Kobold’s patent was valid and infringed by NCS. As a

Three Interesting Issues Raised in the NCS/Kobold Patent Action – Part I Read More »

Angelcare v Munchkin: Entitlement to Infringement Remedies

IP Decisions /

Co-written with Dino Clarizio The Federal Court of Canada (per Roy J.) decided four issues of entitlement to remedies in an action where he had previously held that the defendants’ products sold in Canada infringed valid claims. The issues were 1) entitlement to injunctive relief; 2) entitlement to an accounting of profits; 3) entitlement to

Angelcare v Munchkin: Entitlement to Infringement Remedies Read More »